Identifying the PR3 Cleavage Site
Fibrinogen is a physiological substrate for PR3 and initially, specific fibrinogen cleavage products generated by PR3 (Athens Research and Technology, Athens, GA) were identified by mass spectrometry (MS) and gel electrophoresis as described below.
Matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) analysis (UltrafleXtreme, Bruker) detected a peak in a PR3/fibrinogen digest solution (red peak) but not an NE/fibrinogen digest (green peak). This peak was also present in plasma from patients with AATD (blue profile) as shown in figure E1 . 
Figure E2. Polyacrylamide gel electrophoresis of cleaved and uncleaved fibrinogen (UF).
Neutrophil elastase (NE) Subsequent digestion of band A showed that it was generated by cleavage of the fibrinogen alpha chain on the carboxyl side of K527 by PR3 (see figure E3 ). Further gel electrophoresis and MS analysis demonstrated that the molecular weight of band A is between 56-70kDa suggesting the C-terminus lies between M536 and G548 (underlined). The trypsin (yellow) and Asp-N (blue) cleavage sites closest to the likely C-terminus (bold) also suggested that the PR3 cleavage site was unlikely to lie beyond R547.
These data support the PR3 cleavage lying between K527 and G548 (trypsin specific cleavage sites). Asp-N digest of band A and subsequent MS analysis detected a number of peaks with varying molecular weights. One peak had a molecular weight 2236.08Da, which is consistent with a peptide fragment between D521 and V541.
These data confirm that valine 541 of the fibrinogen alpha chain (Aα-Val 541 ) is the C-terminus of band A and the site of PR3 cleavage. The size of the fibrinogen cleavage product generated (2236Da; D521-V541) was assumed to have a reasonable circulating half-life and be enzyme specific as no such fragment was produced by NE. The carboxyl terminal six amino peptide sequence to Val 541 was then selected as the target to develop a specific assay for this cleavage site.
The Aα-Val 541 Assay
An indirect ELISA was then developed using fibrinogen incubated for 15 minutes at 37°C with PR3 (molar ratio of 1:200 PR3:Fibrinogen and reaction terminated with an excess of 0.1% trifluoroacetic acid) as the antigen to coat 96-well black high bind microplates (Corning, Wiesbaden, Germany) at 4°C overnight. The following day a solution containing 1% bovine serum albumin (BSA) was applied for 1 hour at 37°C to block remaining sites and prevent nonspecific binding. Standard peptide (COMLGEFV) from 0-125nM or samples (15µl plasma added to 60µl block buffer) were incubated with the diluted rabbit antiserum (75µl) overnight at 4°C before being transferred to the coated plate washed with tris-buffered saline, 0.05% Tween 20 (TBST). Following 2 hours incubation the plate was washed again with TBST and DELFIA europium-conjugated anti-rabbit IgG added (concentration 806ng/ml; Perkin Elmer, Seer Green, UK). After 1 hour and a further wash DELFIA enhancement solution (Perkin Elmer, Seer Green, UK) was added to develop the fluorescent signal. Fluorescence was read at 340nm excitation and 620nm emission using a BioTek Synergy 2 plate reader running Gen5 software.
The difference in signal between application of pure antiserum (B0) and that incubated with varying concentrations of peptide (B) was used to derive a standard curve (3-order polynomial trend line) in Excel from which sample results were obtained by interpolation. Titration experiments were conducted to establish the optimal concentrations for both PR3 cleaved fibrinogen and rabbit antiserum used in the assay. Final dilutions were 1:20,000 for the antiserum (sufficient stock to measure 3.5x10 9 samples at this concentration) and 1:16,000 for PR3 cleaved fibrinogen (equivalent to adding ~3.8nM per well). These conditions gave a B/B0 of approximately 16% when using 125nM of peptide, which is comparable to the AαVal 360 assay described previously [10] .
Samples were run in triplicate on each plate and average result taken as for the Aα-Val 360 assay. Pooled plasma from PiZZ patients was used as a control sample and added to every plate. Sample results were only accepted if the control result was within 2 S.D. of the mean obtained from previous replicate samples. Samples from healthy controls and PiZZ AATD patients were able to be measured using the same standard curve.
Validation of the rabbit antiserum used in the assay is described in further detail in the experiments below.
Rabbit Anti-serum
Antibody (serum) from two rabbits (R3839 and R3840) generated by the bovine thyroglobulin linked peptide described in the main text was tested at various concentrations using the assay design described above. Rabbit R3839 gave a better signal in terms of relative fluorescent units (RFU) especially at higher dilutions indicating higher affinity/concentration. The initial results are shown in figure E4 . Aα-Val 360 is a previously described marker of pre-inhibition NE activity in vivo. The peptide used as a standard in the Aα-Val 360 assay is CJTSESSV. We also confirmed that this peptide (which also has a terminal valine) was not recognised by the R3839 antibody ( figure E6 ). 
Measuring PR3 cleaved, NE cleaved or uncleaved fibrinogen
Various concentrations of PR3 cleaved, NE cleaved or uncleaved fibrinogen were added to block buffer and the assay performed as usual.
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Virtually all of the antibody was removed by the PR3 cleaved fibrinogen as shown by a low %B/B0 in figure E7 . NE cleaved fibrinogen and, to a lesser extent, uncleaved fibrinogen do bind the antibody because the cleavage site is already exposed physiologically in these preparations. However, at the lowest concentrations (7.8 -15.6nM) antibody binding is minimal in uncleaved and approximately 9 times less for NE cleaved compared to the complete binding of PR3 cleaved fibrinogen. 
